- Home
- MYNZ vs SNGX Comparison
MYNZ vs SNGX Comparison
Compare MYNZ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- SNGX
- Stock Information
- Founded
- MYNZ 2021
- SNGX 1987
- Country
- MYNZ Germany
- SNGX United States
- Employees
- MYNZ N/A
- SNGX N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- SNGX Health Care
- Exchange
- MYNZ Nasdaq
- SNGX Nasdaq
- Market Cap
- MYNZ 7.6M
- SNGX 6.5M
- IPO Year
- MYNZ 2021
- SNGX 1987
- Fundamental
- Price
- MYNZ $2.04
- SNGX $1.32
- Analyst Decision
- MYNZ Buy
- SNGX Strong Buy
- Analyst Count
- MYNZ 2
- SNGX 1
- Target Price
- MYNZ $14.00
- SNGX $6.00
- AVG Volume (30 Days)
- MYNZ 185.7K
- SNGX 2.7M
- Earning Date
- MYNZ 08-05-2025
- SNGX 08-08-2025
- Dividend Yield
- MYNZ N/A
- SNGX N/A
- EPS Growth
- MYNZ N/A
- SNGX N/A
- EPS
- MYNZ N/A
- SNGX N/A
- Revenue
- MYNZ $893,991.00
- SNGX $2,342.00
- Revenue This Year
- MYNZ $26.06
- SNGX N/A
- Revenue Next Year
- MYNZ $4.97
- SNGX N/A
- P/E Ratio
- MYNZ N/A
- SNGX N/A
- Revenue Growth
- MYNZ N/A
- SNGX N/A
- 52 Week Low
- MYNZ $1.34
- SNGX $1.09
- 52 Week High
- MYNZ $19.00
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- MYNZ 57.11
- SNGX 41.75
- Support Level
- MYNZ $1.89
- SNGX $1.34
- Resistance Level
- MYNZ $2.25
- SNGX $1.46
- Average True Range (ATR)
- MYNZ 0.22
- SNGX 0.11
- MACD
- MYNZ 0.05
- SNGX 0.03
- Stochastic Oscillator
- MYNZ 76.14
- SNGX 62.16
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).